Crazy question but curious

There are no stupid questions,… I was wondering that too….

Hope somebody replies :-))

Patrisa

There are no stupid questions,… I was wondering that too….

Hope somebody replies :-))

Patrisa

There are no stupid questions,… I was wondering that too….

Hope somebody replies :-))

Patrisa

Since anti-PD1 (and even ipi) are relatively new on the market and therefore, patient populations having had these drugs are rather small and rather new (ish) I doubt any retrospective study looking at your sort of question has been done.  But…since intial studies with those drugs were thrown at a large number of cancer patients and only melanoma, small non cell lung cancer patients, and those with renal cell carcinoma responded…I would guess that those are the only cancers for which we may be impacted (at least with anti-PD1).  Here's a history I wrote back in 2013 of the road to where we are today with anti-PD1 therapy in melanoma.

http://chaoticallypreciselifeloveandmelanoma.blogspot.com/2013/06/love-potionor-patient9.html

Interesting to think about, looking back and forward.  Celeste

Since anti-PD1 (and even ipi) are relatively new on the market and therefore, patient populations having had these drugs are rather small and rather new (ish) I doubt any retrospective study looking at your sort of question has been done.  But…since intial studies with those drugs were thrown at a large number of cancer patients and only melanoma, small non cell lung cancer patients, and those with renal cell carcinoma responded…I would guess that those are the only cancers for which we may be impacted (at least with anti-PD1).  Here's a history I wrote back in 2013 of the road to where we are today with anti-PD1 therapy in melanoma.

http://chaoticallypreciselifeloveandmelanoma.blogspot.com/2013/06/love-potionor-patient9.html

Interesting to think about, looking back and forward.  Celeste

Since anti-PD1 (and even ipi) are relatively new on the market and therefore, patient populations having had these drugs are rather small and rather new (ish) I doubt any retrospective study looking at your sort of question has been done.  But…since intial studies with those drugs were thrown at a large number of cancer patients and only melanoma, small non cell lung cancer patients, and those with renal cell carcinoma responded…I would guess that those are the only cancers for which we may be impacted (at least with anti-PD1).  Here's a history I wrote back in 2013 of the road to where we are today with anti-PD1 therapy in melanoma.

http://chaoticallypreciselifeloveandmelanoma.blogspot.com/2013/06/love-potionor-patient9.html

Interesting to think about, looking back and forward.  Celeste